Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd.
- Development stage
- Unknown
- Lead developer
- Neurodawn
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd. is a drug combination regimen utilized in clinical pharmacology studies to evaluate the pharmacokinetic drug-drug interaction (DDI) potential of Y-3, an investigational small molecule developed by Neurodawn Pharmaceutical Co., Ltd. Y-3 is a dual-target therapeutic designed to disrupt the PSD95/nNOS interface and modulate GABA receptors, with primary indications in acute ischemic stroke and post-stroke depression. This specific regimen incorporates repaglinide, warfarin, and omeprazole as sensitive probe substrates for the cytochrome P450 enzymes CYP2C8, CYP2C9, and CYP2C19, respectively. By administering these agents alongside Y-3, researchers can assess whether Y-3 inhibits or induces these metabolic pathways, thereby informing safe co-administration guidelines and the drafting of drug instructions for Y-3 upon potential marketing.
02
Targets
GABRR (GABA-A receptor subunit rho)DLG4 (Disks Large Homolog 4)KATP channel (ATP-sensitive potassium channel)GABA-B (Gamma-aminobutyric acid receptor type B)NOS1 (nNOS)ATP4A (Potassium–transporting ATPase alpha chain 1)VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd..
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on repaglinide + warfarin + omeprazole + Y-3-Neurodawn Pharmaceutical Co., Ltd..